The European Commission has granted Cellectar Biosciences orphan drug designation and 10 years of European market exclusivity for CLR 131 in Waldenstrom’s Macroglobulinemia (WM), the company announced today. “Receipt of European orphan…
Cellectar Biosciences has started a trial for CLR 131 in Waldenstrom’s macroglobulinemia (WM), the company announced recently. According to a release, the trial will include 50 WM patients who will…
NorthStar Medical Radioisotopes received approval from the U.S. Food and Drug Administration (FDA) to produce the isotope Molybdenum-99 (Mo-99) from concentrated Mo-98 (cMo-98), the company announced recently. “This approval of production…
Cellectar Biosciences announced today the pricing of its underwritten public offering of its common stock at $1.35 per share, which will result in gross proceeds of approximately $24.5 million. Cellectar also…
SHINE Medical Technologies broke ground on its 54,000-square-foot corporate headquarters and therapeutics production facility in Janesville, Wis., the company announced recently. “The best work we do at SHINE is the…
SHINE Medical Technologies will add a “supercell,” a bank of 10 hot cells, for its medical isotope production facility in Janesville, Wis., the company announced recently. According to a release,…
Imbed Biosciences announced today the results of a first prospective clinical evaluation of its next-generation wound dressing, Microlyte Matrix, in complex chronic wounds. “This was a very professionally run prospective…
SHINE Medical Technologies Therapeutics division has made its first commercial sale of lutetium-177, a therapeutic isotope in demand by clinical trial sponsors, the company announced recently. “This milestone is really exciting,…
Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. According to…
Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today. According to a release, the Oncotype MAP…
